182 related articles for article (PubMed ID: 19522047)
1. Anti-interleukin-5 therapy and severe asthma.
Gleich GJ
N Engl J Med; 2009 Jun; 360(24):2577; author reply 2578. PubMed ID: 19522047
[No Abstract] [Full Text] [Related]
2. Eosinophils in asthma--closing the loop or opening the door?
Wenzel SE
N Engl J Med; 2009 Mar; 360(10):1026-8. PubMed ID: 19264692
[No Abstract] [Full Text] [Related]
3. Anti-interleukin-5 therapy and severe asthma.
Zarogiannis S; Gourgoulianis KI; Kostikas K
N Engl J Med; 2009 Jun; 360(24):2576; author reply 2577. PubMed ID: 19516040
[No Abstract] [Full Text] [Related]
4. Anti-interleukin-5 therapy and severe asthma.
Szczeklik A
N Engl J Med; 2009 Jun; 360(24):2576-7; author reply 2577. PubMed ID: 19522046
[No Abstract] [Full Text] [Related]
5. Eosinophils and interleukin-5: the debate continues.
Kay AB; Menzies-Gow A
Am J Respir Crit Care Med; 2003 Jun; 167(12):1586-7. PubMed ID: 12796050
[No Abstract] [Full Text] [Related]
6. The role of interleukin 5 in asthma.
Varricchi G; Canonica GW
Expert Rev Clin Immunol; 2016 Sep; 12(9):903-5. PubMed ID: 27450970
[No Abstract] [Full Text] [Related]
7. Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
Castro M; Bacharier LB
Lancet; 2016 Oct; 388(10056):2059-2060. PubMed ID: 27609409
[No Abstract] [Full Text] [Related]
8. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
9. Reslizumab (Cinqair) for severe eosinophilic asthma.
Med Lett Drugs Ther; 2016 Jun; 58(1497):81-2. PubMed ID: 27305070
[No Abstract] [Full Text] [Related]
10. [Severe refractory eosinophilic asthma].
Jäger-Becker D
MMW Fortschr Med; 2016 Feb; 158(3):67. PubMed ID: 27119709
[No Abstract] [Full Text] [Related]
11. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
12. Novel Interleukin-5 Targeted Treatment Options for Severe Eosinophilic Asthma.
Berendse J; Craig B; Gullickson E
S D Med; 2018 Jun; 71(6):274-276. PubMed ID: 30005153
[No Abstract] [Full Text] [Related]
13. [PERSONALIZED TREATMENT OF ASTHMA: THE ISSUE OF ANTI-INTERLEUKIN-5 ANTIBODIES].
Louis R; Demarche S; Van Hees T; Schleich F
Rev Med Liege; 2015; 70(5-6):306-9. PubMed ID: 26285457
[TBL] [Abstract][Full Text] [Related]
14. [Anti-interleukin-5 therapy for eosinophilic diseases].
Simon D; Braathen LR; Simon HU
Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
[TBL] [Abstract][Full Text] [Related]
15. Mepolizumab use: Post-approval academic practice experience.
Benjamin MR; Bochner BS; Peters AT
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):126-128. PubMed ID: 29653234
[No Abstract] [Full Text] [Related]
16. Unsustained Response to Benralizumab in Eosinophilic Asthma After 3 Years of Therapy With Mepolizumab.
Kurosawa M; Shimizu Y; Sutoh Y; Sutoh E
J Investig Allergol Clin Immunol; 2021 Jul; 31(4):353-355. PubMed ID: 33136004
[No Abstract] [Full Text] [Related]
17. TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma.
Mathur M; Herrmann K; Li X; Qin Y; Weinstock J; Elliott D; Monahan J; Padrid P
Am J Respir Crit Care Med; 1999 Feb; 159(2):580-7. PubMed ID: 9927376
[TBL] [Abstract][Full Text] [Related]
18. Anti-IL-5 (mepolizumab) therapy does not alter IL-5 receptor alpha levels in patients with eosinophilic esophagitis.
Conus S; Straumann A; Simon HU
J Allergy Clin Immunol; 2009 Jan; 123(1):269; author reply 269-70. PubMed ID: 18951621
[No Abstract] [Full Text] [Related]
19. Reslizumab: Maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids.
Paton DM
Drugs Today (Barc); 2016 Jun; 52(6):323-9. PubMed ID: 27458609
[TBL] [Abstract][Full Text] [Related]
20. The demise of anti IL-5 for asthma, or not.
O'Byrne PM
Am J Respir Crit Care Med; 2007 Dec; 176(11):1059-60. PubMed ID: 18042659
[No Abstract] [Full Text] [Related]
[Next] [New Search]
